

#4

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Strehlke et al.

Group Art Unit: TBA

Serial No.: 10/078,530

Examiner: TBA

Filed: February 21, 2002

For: QUINOLINE, ISOQUINOLINE AND PHTHALAZINE DERIVATIVES AS ANTAGONISTS OF  
THE GONADOTROPIN-RELEASING HORMONE

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to initial examination, please amend the above-identified application as follows:

**IN THE CLAIMS:**

Please amend the claims as follows:

3. (Amended) Compounds according to claim 1, wherein R1 is the group -CO-R11.
5. (Amended) Compounds according to claim 1, wherein R1 is the group -CO-OR12.
7. (Amended) Compounds according to claim 1, wherein R2 is a 2',5'-difluorobenzyl group.
8. (Amended) Compounds according to claim 1, wherein R3 and R4 are hydrogen atoms.
9. (Amended) Compounds according to claim 1, wherein Z is a direct bond or an oxygen atom.
10. (Amended) Compounds according to claim 1, wherein G - C = C -.
11. (Amended) Compounds according to claim 1, wherein L is an NH group.

12. (Amended) Compounds according to claim 1, wherein Q is a carbonyl group, and R51 is a C<sub>1</sub>-C<sub>6</sub> alkyl group.

13. (Amended) Compounds according to claim 1, wherein R61 is a hydrogen atom or a methyl group and/or R62 is a benzyl group.


14. (Amended) Use of compounds according to claim 1 as antagonists of the gonadotropin-releasing hormone (GnRH).

**REMARKS**

The claims have been amended to remove the multiple dependency therein.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Richard J. Traverso, Reg. No. 30,595  
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza 1, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1805

Date: September 3, 2002

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE CLAIMS:**

Please amend the claims as follows:

3.     (Amended) Compounds according to claim 1 ~~or 2~~, wherein R1 is the group -CO-R11.
5.     (Amended) Compounds according to claim 1 ~~or 2~~, wherein R1 is the group -CO-OR12.
7.     (Amended) Compounds according to ~~one of claims 1 to 6~~ claim 1, wherein R2 is a 2',5'-difluorobenzyl group.
8.     (Amended) Compounds according to ~~one of claims 1 to 7~~ claim 1, wherein R3 and R4 are hydrogen atoms.
9.     (Amended) Compounds according to ~~one of claims 1 to 8~~ claim 1, wherein Z is a direct bond or an oxygen atom.
10.    (Amended) Compounds according to ~~one of claims 1 to 9~~ claim 1, wherein G - C = C -.
11.    (Amended) Compounds according to ~~one of claims 1 to 10~~ claim 1, wherein L is an NH group.
12.    (Amended) Compounds according to ~~one of claims 1 to 11~~ claim 1, wherein Q is a carbonyl group, and R51 is a C<sub>1</sub>-C<sub>6</sub> alkyl group.
13.    (Amended) Compounds according to ~~one of claims 1 to 12~~ claim 1, wherein R61 is a hydrogen atom or a methyl group and/or R62 is a benzyl group.
14.    (Amended) Use of compounds according to ~~one of claims 1 to 13~~ claim 1 as antagonists of the gonadotropin-releasing hormone (GnRH).